icon-folder.gif   Conference Reports for NATAP  
 
  66th Annual Meeting of the
American Association for the
Study of Liver Diseases
Boston, MA Nov 13-17 2015		 Back grey_arrow_rt.gif
 
 
 
Safety and Efficacy of Treatment With Daily Sofosbuvir 400 mg + Ribavirin 200 mg for 24 Weeks in Genotype 1 or 3 HCV-Infected Patients With Severe Renal Impairment
 
 
  Reported by Jules Levin
 
Paul Martin,1 Edward Gane,2 Grisell Ortiz-Lasanta,3 Lin Liu,4 Karim Sajwani,4 Brian Kirby,4 Luisa M. Stamm,4 Diana M. Brainard,4 John G. McHutchison,4 Eric Lawitz,5 Stuart Gordon,6 Richard Robson7
1University of Miami, FL; 2Auckland City Hospital, Auckland, New Zealand; 3Fundacion de Investigacion, Rio Piedras, PR; 4Gilead Sciences, Inc., Foster City, CA; 5The Texas Liver Institute, UT Health Science Center, San Antonio, TX; 6Henry Ford Health System, Detroit, MI; 7Christchurch Clinical Studies Trust Ltd, Christchurch, New Zealand

AASLD1.gif

AASLD2.gif

AASLD3.gif

AASLD4.gif

AASLD5.gif

AASLD6.gif

AASLD7.gif

AASLD8.gif

AASLD9.gif

AASLD10.gif

AASLD11.gif

AASLD12.gif

AASLD13.gif

References
 
1. HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C. hcvguidelines.org; 2. Cornpropst M, et al. EASL 2012, poster 1101; 3. Gane E, et al. AASLD 2014, poster 966; 4. Sulkowski MS, et al. JAMA 2014;312:353-61.